BRISTOL MYERS SQUIBB
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
- Conditions
- Hepatitis C
- Interventions
- First Posted Date
- 2013-10-31
- Last Posted Date
- 2015-10-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 202
- Registration Number
- NCT01973049
- Locations
- 🇺🇸
Scripps Clinic, La Jolla, California, United States
🇺🇸Binghamton Gastroenterology Associates, Binghamton, New York, United States
🇺🇸Weill Cornell Medical College, New York, New York, United States
An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
- Conditions
- Neoplasms by Site
- Interventions
- Biological: RelatlimabBiological: BMS-986213Biological: Nivolumab
- First Posted Date
- 2013-10-23
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1499
- Registration Number
- NCT01968109
- Locations
- 🇺🇸
Local Institution - 0010, Pittsburgh, Pennsylvania, United States
🇺🇸Local Institution - 0057, Dallas, Texas, United States
🇺🇸Local Institution - 0043, La Jolla, California, United States
A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors
- Conditions
- Advanced or Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2013-08-23
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1163
- Registration Number
- NCT01928394
- Locations
- 🇺🇸
Local Institution - 0001, Atlanta, Georgia, United States
🇺🇸Local Institution - 0007, Portland, Oregon, United States
🇺🇸Local Institution - 0002, Nashville, Tennessee, United States
Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma
- Conditions
- Metastatic MelanomaUnresectable Melanoma
- Interventions
- First Posted Date
- 2013-08-22
- Last Posted Date
- 2022-03-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 142
- Registration Number
- NCT01927419
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)
- Conditions
- Newly Diagnosed, Previously Untreated Multiple Myeloma
- Interventions
- First Posted Date
- 2013-07-03
- Last Posted Date
- 2021-07-01
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 23
- Registration Number
- NCT01891643
- Locations
- 🇺🇸
Crescent City Research Consortium, LLC, Marrero, Louisiana, United States
🇺🇸Illinois Cancercare, Pc, Peoria, Illinois, United States
🇺🇸Memorial Cancer Institute, Hollywood, Florida, United States
Study to Characterize the Pharmacokinetics of a Single Dose of SC Abatacept 125 mg Using the BD Autoinjector or the Prefilled Syringe
- First Posted Date
- 2013-07-01
- Last Posted Date
- 2015-11-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 356
- Registration Number
- NCT01890473
- Locations
- 🇺🇸
Physician Research Collaboration, Llc, Lincoln, Nebraska, United States
🇿🇦Local Institution, George, Western Cape, South Africa
🇺🇸Rheumatology Associates Of North Alabama, P.C., Huntsville, Alabama, United States
Study of the Pharmacokinetics and Safety of Asunaprevir in Patients With Kidney Disease
- First Posted Date
- 2013-06-26
- Last Posted Date
- 2013-11-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 48
- Registration Number
- NCT01886599
- Locations
- 🇺🇸
Davita Clinical Research, Minneapolis, Minnesota, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸New Orleans Center For Clinical Research, Knoxville, Tennessee, United States
Eliquis Regulatory Post Marketing Surveillance (rPMS)
- First Posted Date
- 2013-06-25
- Last Posted Date
- 2016-02-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 100
- Registration Number
- NCT01885585
- Locations
- 🇰🇷
Local Institution, Seoul, Korea, Republic of
Eliquis Regulatory Post Marketing Surveillance
- First Posted Date
- 2013-06-25
- Last Posted Date
- 2017-10-31
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 3335
- Registration Number
- NCT01885598
- Locations
- 🇰🇷
Local Institution, Seoul, Korea, Republic of
Multi-center Study to Evaluate the Safety of Apixaban (BMS-562247) in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement Surgery
- First Posted Date
- 2013-06-24
- Last Posted Date
- 2019-11-29
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 557
- Registration Number
- NCT01884337
- Locations
- 🇮🇳
Local Institution, Pune, India